PMI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Picard Medical Inc (PMI) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently facing significant legal challenges, weak technical indicators, and a lack of positive trading signals. Additionally, the financial performance, while showing some revenue growth, remains unprofitable with declining gross margins. The absence of strong positive catalysts or influential support further weakens its investment appeal.
The technical indicators show a bearish trend with SMA_200 > SMA_20 > SMA_5, indicating downward momentum. The RSI is neutral at 34.017, and the MACD histogram is above 0 but positively contracting, suggesting no strong upward momentum. The stock is trading below key pivot levels, with support at 1.011 and resistance at 1.303.
The company reported a 12.5% revenue growth for FY 2025 and a 34.73% YoY revenue increase in Q3 2025, alongside an increase in cash reserves.
Picard Medical is facing multiple class action lawsuits alleging securities fraud and involvement in a fraudulent stock promotion scheme. Gross margin dropped significantly by -85.67% YoY, and the stock has a 60% probability of declining further in the short term.
In Q3 2025, revenue increased by 34.73% YoY to $1,187,000, but the company remains unprofitable with a net income of -$10,426,000 (up 51.34% YoY). EPS improved to -0.14 (up 40% YoY), but gross margin fell sharply to -10.95%, indicating operational inefficiencies.
No analyst rating or price target data is available.
